Enterprise Value
9.661B
Cash
1.434B
Avg Qtr Burn
-210.3M
Short % of Float
7.19%
Insider Ownership
34.48%
Institutional Own.
58.52%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VTAMA (Tapinarof) Details Psoriasis | Approved Quarterly sales | |
VTAMA (Tapinarof) Details Atopic dermatitis | sNDA Submission | |
Batoclimab Details Eye disease , Thyroid Eye Disease | Phase 3 Data readout | |
Batoclimab Details Myasthenia gravis | Phase 3 Data readout | |
Brepocitinib Details Diabetes mellitus , Systemic lupus erythematosus Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
RVT-3101 Details Ulcerative colitis | Phase 3 Initiation | |
RVT-3101 Details Crohns disease | Phase 2 Data readout | |
Namilumab Details Sarcoidosis | Phase 2 Data readout | |
RVT-2001 Details Myelodysplastic syndrome | Phase 1/2 Data readout |